Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Fabio Giuseppe Liberante, Tara Pouryahya, Mary-Frances McMullin, Shu-Dong Zhang*, Kenneth Ian Mills*

    Research output: Contribution to journal › Article

    1 Downloads (Pure)
    Original languageEnglish
    JournalOncotarget
    Volume7
    Issue number6
    Publication statusPublished - 28 Dec 2015

    Keywords

    • myelodysplastic syndromes (MDS)
    • acute myeloid leukemia (AML)
    • bromocriptine
    • re-purposed
    • therapy

    Cite this

    Liberante, Fabio Giuseppe ; Pouryahya, Tara ; McMullin, Mary-Frances ; Zhang*, Shu-Dong ; Mills*, Kenneth Ian. / Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. In: Oncotarget. 2015 ; Vol. 7, No. 6.
    @article{63c950ee3b3640d8816cf5af351b55c5,
    title = "Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia",
    keywords = "myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), bromocriptine, re-purposed, therapy",
    author = "Liberante, {Fabio Giuseppe} and Tara Pouryahya and Mary-Frances McMullin and Shu-Dong Zhang* and Mills*, {Kenneth Ian}",
    year = "2015",
    month = "12",
    day = "28",
    language = "English",
    volume = "7",
    journal = "Oncotarget",
    issn = "1949-2553",
    number = "6",

    }

    Liberante, FG, Pouryahya, T, McMullin, M-F, Zhang*, S-D & Mills*, KI 2015, 'Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia', Oncotarget, vol. 7, no. 6.

    Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. / Liberante, Fabio Giuseppe; Pouryahya, Tara; McMullin, Mary-Frances; Zhang*, Shu-Dong; Mills*, Kenneth Ian.

    In: Oncotarget, Vol. 7, No. 6, 28.12.2015.

    Research output: Contribution to journal › Article

    TY - JOUR

    T1 - Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

    AU - Liberante, Fabio Giuseppe

    AU - Pouryahya, Tara

    AU - McMullin, Mary-Frances

    AU - Zhang, Shu-Dong

    AU - Mills, Kenneth Ian

    PY - 2015/12/28

    Y1 - 2015/12/28

    KW - myelodysplastic syndromes (MDS)

    KW - acute myeloid leukemia (AML)

    KW - bromocriptine

    KW - re-purposed

    KW - therapy

    M3 - Article

    VL - 7

    JO - Oncotarget

    JF - Oncotarget

    SN - 1949-2553

    IS - 6

    ER -

    Liberante FG, Pouryahya T, McMullin M-F, Zhang* S-D, Mills* KI. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget. 2015 Dec 28;7(6).

    Access to Document